5 March 2025
BSF Enterprise
PLC
("BSF" or
the "Company")
Result of
Annual General Meeting
BSF Enterprise (BSFE), through its
3D Bio-Tissues (3DBT) subsidiary, is transforming the biotech
landscape with innovative technologies that include scaffold-free
tissue engineered materials and patented macromolecular crowders,
used as media additives to optimize cell growth.
The Company is pleased to announce
that at the Company's Annual General Meeting held earlier today,
all resolutions proposed were duly passed by shareholders by way of
a poll, the results of which were as follows:
|
Resolution
|
Poll
Results
|
|
For
|
Against
|
Withheld
|
Discretionary
|
Total
|
|
1
|
Shares
|
74,812,766
|
-
|
-
|
-
|
74,812,766
|
|
%
|
100.00%
|
-
|
-
|
-
|
100%
|
|
2
|
Shares
|
73,512,766
|
1,309,210
|
10,000
|
-
|
74,831,976
|
|
%
|
98.24%
|
1.75%
|
-
|
-
|
100%
|
|
3
|
Shares
|
73,512,766
|
1,309,210
|
10,000
|
-
|
74,831,976
|
|
%
|
98.24%
|
1.75%
|
-
|
-
|
100%
|
|
4
|
Shares
|
60,137,512
|
1,756,487
|
10,000
|
-
|
61,903,999
|
|
%
|
97.15%
|
2.84%
|
|
-
|
100%
|
|
5
|
Shares
|
73,512,766
|
1,309,210
|
10,000
|
-
|
74,831,976
|
|
%
|
98.24%
|
1.75%
|
0.01%
|
-
|
100%
|
|
6
|
Shares
|
74,812,766
|
-
|
19,210
|
-
|
74,831,976
|
|
%
|
99.97%
|
-
|
-
|
-
|
100%
|
|
7
|
Shares
|
73,060,970
|
1,751,796
|
19,210
|
-
|
74,831,976
|
|
%
|
97.63%
|
2.34%
|
-
|
-
|
100%
|
|
8
|
Shares
|
73,065,489
|
1,747,277
|
19,210
|
-
|
74,831,976
|
|
%
|
97.64%
|
2.33%
|
0.03%
|
|
100%
|
|
9
|
Shares
|
74,812,766
|
-
|
19,210
|
-
|
74,831,976
|
|
%
|
99.97%
|
-
|
0.03%
|
-
|
100%
|
About BSF Enterprise PLC:
BSF Enterprise PLC (BSF) is the
parent to a portfolio of innovative subsidiary companies focused on
developing and commercialising cell-based tissue engineering
solutions to deliver sustainable outcomes across a variety of
sectors. Its portfolio of subsidiaries is as follows:
-
3DBT: A pioneering UK-based
tissue engineering company that has developed scaffold-free tissue
production processes as well as leading on the commercial use of
macromolecular crowders to transform cell culture.
-
Lab-Grown Leather
Ltd: A company focused on the
customer driven development of cultivated skin technology to
produce sustainable leather.
-
Kerato
Ltd: A tissue engineering company
with patent-protected IP that is focussing on commercialising
technologies for corneal repair with veterinary trials starting
2025 .
-
BSF Enterprise
(Hong Kong) Limited: A company
established to actively support commercialisation of BSF's
technology in China and Asia.
-
Cultured Meat
Technologies (CMT): A 100% owned
company, using technology developed within 3DBT, successfully
produced the UK's first high-quality cultivated meat. Currently
focused on providing the market with the premier platform for
manufacturing cultivated meat in a scalable and cost-competitive
manner.
BSF's core strategy is to acquire,
invest in, or develop joint ventures with, the most promising
companies from across the industry. In doing so BSF intends to
create an environment in which its portfolio of companies can
flourish and collaborate, thereby accelerating their progress,
potential and time to market.
For further enquiries, please visit
www.bsfenterprise.com or contact:
Geoff Baker - Executive
Director
Che Connon - CEO &
Director
Shard Capital (Broker):
Damon Heath 0207 186 9000
Isabella Pierre 0207 186
9927
